|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Merck |
|---|---|
| Information provided by: | Merck |
| ClinicalTrials.gov Identifier: | NCT00533481 |
Purpose
Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.
| Condition | Intervention | Phase |
|---|---|---|
|
Obesity |
Drug: MK0557 |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study |
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | 2007_615 |
| Study First Received: | September 19, 2007 |
| Last Updated: | September 19, 2007 |
| ClinicalTrials.gov Identifier: | NCT00533481 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Sibutramine Body Weight Signs and Symptoms Obesity |
Orlistat Nutrition Disorders Overweight Overnutrition |
|
Body Weight Signs and Symptoms Obesity |
Nutrition Disorders Overweight Overnutrition |